European Capital Investment Review 2017: Pharmaceutical-Biotech Industry Launched $13 Billion in Capital Construction Starts

---

Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Considered a key component of Europe's industrial base, the European Pharmaceutical & Biotech Industry includes the development and production of pharmaceuticals, biologicals, medical devices and cosmetics. Continuing to return a healthy capital expenditure investment profile along with consistent project activity, Europe launched nearly $13 billion in capital and maintenance Pharma-Biotech projects in 2017.

Click on the image at right for a graph detailing European Pharmaceutical-Biotech kickoffs in 2017.

Divided among 505 projects, the $13 billion returned a robust average total investment value (TIV) of $25.7 million. The individual projects range from a $1 million equipment upgrade at a controlled-release contract manufacturing (CMO) plant in Hlohovec, West Slovakia, to a $900 million cell culture production plant addition in Wein, Germany. All of this activity is not entirely unexpected. The very nature of the projects is a great representation of the industry's diverse and global pedigree. From contact lenses to biological drug development and production, a large number of the major companies reported on in Europe have a strong North American presence as well.

A sampling from the 2017 includes the $562 million "Genesis" project in Ulm, Germany. TEVA GmbH (Ulm) is expanding its existing plant to add capacity--two 15,000-liter bioreactors--for biosimilars production, as well as APIs and monoclonal antibodies. Construction is expected to be complete in 2021. Project team members include Architekt Podsedensek ZT (Vienna, Austria) and ALLPLAN Gesellschaft mbH (Vienna, Austria). For more information, see Industrial Info's project report.

In Italy, Aesica Pharmaceuticals (Torino, Italy) is investing $1.25 million for a project that includes the addition of an isolator on its bottle filling line. This will give the CMO increased liquid-filling capacity at the site in Torino, which also produces oral doses and injectable products. The IMA Group (Ozzano dell'Emilia, Italy) is serving as the turnkey contractor. For more information, see Industrial Info's project report.

Click here for the 2018 North America Pharmaceutical & Biotech Industry Outlook.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.